Inhibrx Biosciences, Inc. INBX 深 滬
等待開盤 04-02 09:30:00 美东时间
67.05
-0.180
-0.27%
華盛通- 最 高71.65
- 今 開68.76
- 成交量 17.86万股
- 最 低 67.05
- 昨 收 67.23
- 總市值 9.79亿
- 52周最高 94.565
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 10.84
- 委 比 77.30%
- 總股本 1460.70万
- 歷史最高 94.565
- 量 比 0.78
- 振 幅 6.84%
- 歷史最低 7.67
- 每 手 1
- 風險率 28.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Inhibrx Announces Participation in Upcoming Scientific Conference
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic t...
03-03 05:00
Why Inhibrx's Recent Strength May Not Be Built to Last
Adhishthana.com analyses Inhibrx's sharp rally after trial results, highlighting a timing mismatch in the cycle and risks investors should watch.
2025-12-24 20:34
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3
2025-12-17 06:03
Inhibrx Biosciences Reports Promising Q3 2025 Results
Inhibrx Biosciences, Inc. ( ($INBX) ) has released its Q3 earnings. Here is a b...
2025-11-25 11:57
Earnings Scheduled For November 14, 2025
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
2025-11-14 19:11
Inhibrx Biosciences Unveils Positive Phase 2 Results for DR5 Agonist Ozekibart in Chondrosarcoma
Inhibrx Biosciences Inc., a clinical-stage biopharmaceutical company, has announced upcoming presentations of clinical data related to its novel tetravalent Death Receptor 5 (DR5) agonist, ozekibart (...
2025-11-05 05:02
美股周涨跌榜 | RNA周内大涨42.1%！获诺华120亿美元收购；阿根廷概念股全线飙升
RNA周内大涨42.1%，获诺华120亿美元收购；阿根廷概念股全线飙升，SUPV涨84.5%、END涨71.9%>>
2025-11-01 10:35
创胜集团-B(06628.HK)合作伙伴Inhibrx公布ozekibart II期临床试验积极结果
【财华社讯】创胜集团-B(06628.HK)公布，合作伙伴Inhibrx Biosciences, Inc.(纳斯达克代码：INBX)公布了注册性临床研究Ch...
2025-10-31 09:57
美股牛股 | Wellgistics Health涨185.4%；INHIBRX涨102%
Wellgistics Health涨185.4%；INHIBRX涨102.0%；Genenta Science S.p.A.涨92.0%
2025-10-25 16:28
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
2025-10-24 15:05
